U.S. markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.86 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.14 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    107.74
    -0.69 (-0.64%)
     
  • Gold

    1,807.50
    +6.00 (+0.33%)
     
  • Silver

    19.73
    +0.06 (+0.32%)
     
  • EUR/USD

    1.0444
    +0.0017 (+0.17%)
     
  • 10-Yr Bond

    2.8890
    0.0000 (0.00%)
     
  • GBP/USD

    1.2121
    +0.0018 (+0.15%)
     
  • USD/JPY

    135.3980
    +0.2230 (+0.16%)
     
  • BTC-USD

    19,144.23
    +155.48 (+0.82%)
     
  • CMC Crypto 200

    413.00
    -7.14 (-1.70%)
     
  • FTSE 100

    7,234.38
    +65.73 (+0.92%)
     
  • Nikkei 225

    26,153.81
    +218.19 (+0.84%)
     

HMNC Brain Health to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond on June 27, 2022

·1 min read

MUNICH, Germany, June 23, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “Company”), a global clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, announced today that HMNC’s management team will present virtually at the H.C. Wainwright 1st Annual Mental Health Conference taking place on June 27, 2022.

A recording of HMNC’s presentation will be available beginning Monday, June 27 at 7:00 a.m. Eastern Time. The recorded presentation will be accessible through the following webcast link for 90 days: https://journey.ct.events/view/7c3a12b5-8355-4214-903e-3b80a6222aa7.

HMNC Brain Health’s management team will be available for one-on-one meetings throughout the conference. To schedule a meeting, please contact KCSA Strategic Communications at HMNCBrain@kcsa.com.

About HMNC Brain Health

HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission rates. The Company develops a unique pipeline for targeting both Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). The Company has operations both in the US and Germany and is backed by a renowned global VC, several family offices, and a strategic healthcare investor. The Company now enters the next stage of its development with a large-scale licensing and fundraising agenda.

Media Contacts
Alexander Schmidt (Europe)
+49 151 22 99 39 765
alexander.schmidt@gaulyadvisors.com

Anne Donohoe (U.S.)
+1 212-896-1265
hmncbrain@kcsa.com

Investor Contact (U.S.)
Sophia Bashford
+1 929 246 7307
hmncbrain@kcsa.com